An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 30 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.

Trial Profile

An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 30 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 20 Sep 2016 Results from this and other two open label studies ( profiles 240013 and 239811), presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 01 Sep 2015 Primary endpoint (MADRS Total Score change from baseline to Week 12 [ Time Frame: Week 12 ] has been met as per results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top